Navigation Links
Botaneco signs feasibility agreement with Croda to develop specialty crop oil formulation
Date:4/30/2008

Program will focus on evaluation of Botaneco's technology to add

functionality to Echium oil

TSX symbol: SBS

CALGARY, April 30 /PRNewswire-FirstCall/ - Botaneco, a wholly-owned subsidiary of SemBioSys Genetics Inc., today announced that it has signed a feasibility agreement with Croda Enterprise Technology, part of Croda International Plc, an international manufacturer of speciality ingredients with 2007 sales of pnds stlg 886.1m. Croda will evaluate the ability of Botaneco's technology platform to improve the stability and versatility of Echium Plantagineum (Echium) oil, a speciality oil containing omega-3 fatty acids. Under the terms of the agreement, Botaneco will provide Croda with material for purposes of chemical and functional analysis, and to determine the viability of a commercial-scale manufacturing process.

"This feasibility agreement with Croda demonstrates the breadth of products and opportunities we can offer our customers and partners with Botaneco's technology platform," said Andrew Baum, President and CEO of SemBioSys. "We believe that the potential of our platform to improve the stability of oils and other labile materials expand the utility and opportunity for Croda's Echium oil in food, dietary supplements and personal care applications. We expect to complete the study and provide Croda with a defined process for manufacturing commercial amounts of material by the end of 2008."

Echium oil contains stearidonic acid, which is effectively metabolized to eicosapentanoic acid (EPA). EPA has been shown to reduce the risk of coronary heart disease and provide anti-inflammatory benefits in both topical and oral formulations.

About Botaneco

Botaneco is the global developer and marketer of innovative oleosome-based ingredients to the personal care and OTC topical markets. As a technologically driven provider of high performance, proprietary oleosome-based ingredients, Botaneco is committed to developing groundbreaking ingredients that offer multifunctional, tangible and documented benefits to both formulators and consumers. Botaneco's manufacturing facility is located in Calgary, Canada while its sales and marketing and research and development laboratories are in Bensalem PA. More information is available and can be accessed at http://www.botaneco.ca.

About SemBioSys Genetics Inc. (http://www.sembiosys.com)

Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead pharmaceutical candidates, produced in the plant host safflower, are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AI, a next generation cardiovascular drug. In addition to its pharmaceutical products, SemBioSys is developing a series of non-pharmaceutical products addressing human topical, nutritional oils and animal health markets. More information is available and can be accessed at http://www.sembiosys.com.

About Croda International Plc

Croda International is a UK-based manufacturer of speciality ingredients derived mainly from naturally occurring and renewable raw materials. The market-driven company is renowned for its scientific and technological focus, supplying innovative and sustainable ingredients to global consumer care and industrial specialities markets. Its broad product range includes skin, hair and sun care actives, proteins and derivatives, high purity lipid concentrates, lanolins, and polymeric surfactants used in many personal care, home care, health care and crop care applications. Globally Croda International Plc had sales of pnds stlg 886.1m (USD1.76b) in 2007, and recorded a pre-tax trading profit of pnds stlg 60.9m (USD121.2m) for continuing operations. The group employs over 3700 people worldwide, with an extensive sales and distribution network covering more than 60 countries. http://www.croda.com

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at http://www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.


'/>"/>
SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Botaneco Announces Launch of Second Generation Oleosome Product
2. Botaneco obtains $2.4 million in funding from AVAC
3. DelSite Signs Technology Evaluation Agreement With Global Pharmaceutical Company for GelSite(R) Polymer
4. Leslie J. Browne Resigns as President and Chief Executive Officer of Pharmacopeia, Inc.
5. Ratcliff Designs Hospital of the Future for John Muir Medical Center - Walnut Creek Campus
6. CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies
7. AMDL Signs Exclusive Licensing Agreement for Human Papilloma Virus Diagnostic Test Kit in Certain Asian Countries
8. Pharsight Signs Two New DMX(R) License Customers
9. Siemens Signs Multi-Year Agreement With Cleveland Clinic to Deploy Enterprise-Wide Cardiology PACS
10. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in Germany
11. Cardiac Science Signs Letter of Intent With Misys Healthcare Systems to Connect With Their EMR Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... , ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension ... are higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... bottom of the cuvette holder. , FireflySci has developed several Agilent flow cell ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the launch of the Supplyframe Design Lab . Located in Pasadena, Calif., ... the future of how hardware projects are designed, built and brought to market. ...
Breaking Biology Technology:
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
Breaking Biology News(10 mins):